Olaparib – a drug developed through UK-led and funded science – has been shown to cut the risk of cancer recurrence and improve survival rates when added to standard treatment for patients diagnosed with high-risk early-stage breast cancer who have inherited faults in their BRCA1 or BRCA2 genes.
The draft decision, which was announced by NICE, follows unsuccessful attempts to widen access to olaparib for a range of cancers linked to BRCA1 and BRCA2 gene mutations, including advanced prostate cancer and advanced breast cancer…
